Lora Strum , ACLU; AMP v. Myriad: The Fight to Take Back Our Genes
"Ten years after the Supreme Court invalidated the patents on two human genes in AMP v. Myriad, we revisit the landmark case amid renewed calls for gene patenting."
Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD
Lora Strum , ACLU; AMP v. Myriad: The Fight to Take Back Our Genes
"Ten years after the Supreme Court invalidated the patents on two human genes in AMP v. Myriad, we revisit the landmark case amid renewed calls for gene patenting."
"This week, the biggest science-patent dispute in decades is getting a hearing at the U.S. Patent and Trademark Office headquarters. The invention in dispute is the gene-editing technique CRISPR, and at stake are millions, maybe even billions, of dollars for the winning side. CRISPR is the hugely hyped technology that could launch life-saving therapies, novel genetically modified crops, new forms of mosquito control, and more. It could—without much exaggeration—change the world. Any company that wants to use CRISPR will have to license it from the patent dispute’s winner. Both parties embroiled in this fight are universities: MIT and the University of California, Berkeley, whose lawyers represent rival groups of scientists with claims to have first invented CRISPR. The Berkeley group published their work and filed for a patent first, by a few months—but the patent office ended up awarding a patent to the MIT group, due to some complicated procedural rules. The legal and scientific details of the dispute get pretty arcane pretty fast, but you can read some excellent reporting here, here, and here."